2012
DOI: 10.1097/cco.0b013e328352ea02
|View full text |Cite
|
Sign up to set email alerts
|

Rectal cancer

Abstract: At this time, the use of oxaliplatin or targeted agents as component of multimodality treatment for rectal cancer outside of a clinical trial is not recommended. The inclusion of different treatment options, according to tumor stage, location, imaging features, and response, will render the multimodal treatment approach of rectal cancer more risk-adapted.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
13
0
1

Year Published

2013
2013
2018
2018

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 35 publications
(14 citation statements)
references
References 38 publications
0
13
0
1
Order By: Relevance
“…Only 17 (26 %) patients were pN+ in the final histopathological workup while 58 (89 %) had initially been staged mriN+. This huge 63 % gap cannot only be explained by a possible downstaging effect of nCRT, because reported pathological complete remissions vary between 13 and 21 % [14] and only 11 % in this study. The valid treatment guidelines for patients with rectal cancer in Germany during the time period of this study recommended nCRT for patients with clinical evidence for N+ but did not specify on any diagnostic guidelines on how to asses this by MRI [15].…”
Section: Discussionmentioning
confidence: 49%
“…Only 17 (26 %) patients were pN+ in the final histopathological workup while 58 (89 %) had initially been staged mriN+. This huge 63 % gap cannot only be explained by a possible downstaging effect of nCRT, because reported pathological complete remissions vary between 13 and 21 % [14] and only 11 % in this study. The valid treatment guidelines for patients with rectal cancer in Germany during the time period of this study recommended nCRT for patients with clinical evidence for N+ but did not specify on any diagnostic guidelines on how to asses this by MRI [15].…”
Section: Discussionmentioning
confidence: 49%
“…Preoperative CRT followed by radical surgical resection represents the standard of care for patients with locally advanced rectal cancer (4,11,26). However, the response of individual tumors to preoperative multimodal treatment is highly heterogeneous and ranges from complete clinical response to absence of any histopathological tumor regression (complete resistance).…”
Section: Discussionmentioning
confidence: 99%
“…We suggest that targeting Wnt/β-catenin signaling or one of the downstream pathways represent a promising strategy to increase therapeutic responsiveness of rectal cancers to CRT, the standard treatment for patients with locally advanced stages of this disease (4,11,26). …”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This tissue was chosen for this study because with a continuously increasing incidence, colorectal cancer has become one of the three most frequent cancers in the western world [16]. One third of the colorectal cancers are rectal cancers and despite of advances in diagnostics and multimodality treatment using pre-operative (neoadjuvant) chemoradiotherapy followed by extended oncological TME-surgery, the long-term prognosis of patients with locally advanced rectal cancer is limited by the occurrence of distant metastases in nearly 30% of patients [17][19].…”
Section: Introductionmentioning
confidence: 99%